For checkpoint inhibition, PDL1 has been proposed as a putative biomarker, as pembrolizumab (anti-PD 1) is approved in non-small-cell lung carcinoma (NSCLC) only in patients whose tumor PD-L1 levels are ≥50% [32]. The gene discussed is RPL17; the disease is neoplasm.